Cargando…

Myeloid cells as target of fingolimod action in multiple sclerosis

OBJECTIVE: To track the effects of fingolimod, an approved drug for multiple sclerosis (MS), on the activation of myeloid cells from the periphery to the CNS. METHODS: In vitro and ex vivo immunologic studies coupled with flow cytometry were performed to evaluate the action of fingolimod on lipopoly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Dario, Marco, Colombo, Emanuela, Govi, Chiara, De Feo, Donatella, Messina, Maria José, Romeo, Marzia, Sangalli, Francesca, Moiola, Lucia, Rodegher, Mariaemma, Martino, Gianvito, Martinelli, Vittorio, Comi, Giancarlo, Farina, Cinthia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635549/ https://www.ncbi.nlm.nih.gov/pubmed/26587553 http://dx.doi.org/10.1212/NXI.0000000000000157

Ejemplares similares

Dysregulation of MS risk genes and pathways at distinct stages of disease
por: Srinivasan, Sundararajan, et al.
Publicado: (2017)

The Communication of Multiple Sclerosis Diagnosis: The Patients' Perspective
por: Messina, Maria Josè, et al.
Publicado: (2015)

Inferring Multiple Sclerosis Stages from the Blood Transcriptome via Machine Learning
por: Acquaviva, Massimo, et al.
Publicado: (2020)

Loss of Circulating CD8+ CD161(high) T Cells in Primary Progressive Multiple Sclerosis
por: Acquaviva, Massimo, et al.
Publicado: (2019)

Impact of MS genetic loci on familial aggregation, clinical phenotype, and disease prediction
por: Esposito, Federica, et al.
Publicado: (2015)

Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration
por: Colombo, Emanuela, et al.
Publicado: (2020)

Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis
por: Passerini, Gabriella, et al.
Publicado: (2016)

Prognostic value of serum neurofilaments in patients with clinically isolated syndromes
por: Dalla Costa, Gloria, et al.
Publicado: (2019)

Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression
por: Preziosa, Paolo, et al.
Publicado: (2022)

Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
por: Colombo, Emanuela, et al.
Publicado: (2020)

Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach
por: Ferrè, Laura, et al.
Publicado: (2023)

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?
por: Orrico, Mario, et al.
Publicado: (2021)

Author Correction: Transcriptional dysregulation of Interferome in experimental and human Multiple Sclerosis
por: Srinivasan, Sundararajan, et al.
Publicado: (2018)

Transcriptional dysregulation of Interferome in experimental and human Multiple Sclerosis
por: Srinivasan, Sundararajan, et al.
Publicado: (2017)

The phenotypic convergence between microglia and peripheral macrophages during development and neuroinflammation paves the way for new therapeutic perspectives
por: Grassivaro, Francesca, et al.
Publicado: (2020)

Selective killing of spinal cord neural stem cells impairs locomotor recovery in a mouse model of spinal cord injury
por: Cusimano, Melania, et al.
Publicado: (2018)

Changes in cortical motor outputs after a motor relapse of multiple sclerosis
por: Chieffo, Raffaella, et al.
Publicado: (2019)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

iAstrocytes do not restrain T cell proliferation in vitro
por: Colombo, Emanuela, et al.
Publicado: (2023)

In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis
por: Vabanesi, Marco, et al.
Publicado: (2019)

Star Trk(B): The astrocyte path to neurodegeneration
por: Colombo, Emanuela, et al.
Publicado: (2012)

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience
por: S., Guerrieri, et al.
Publicado: (2021)

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
por: Laroni, Alice, et al.
Publicado: (2014)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
por: Diotti, Roberta Antonia, et al.
Publicado: (2016)

Leukocyte Counts and Ratios Are Predictive of Stroke Outcome and Hemorrhagic Complications Independently of Infections
por: Semerano, Aurora, et al.
Publicado: (2020)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis
por: Camacho-Toledano, Celia, et al.
Publicado: (2022)

In Vivo Fate Analysis Reveals the Multipotent and Self-Renewal Features of Embryonic AspM Expressing Cells
por: Marinaro, Cinzia, et al.
Publicado: (2011)

Successful treatment of HIV-associated tumefactive demyelinating lesions with corticosteroids and cyclophosphamide: a case report
por: Lazzarin, Serena Marita, et al.
Publicado: (2020)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

T Regulatory Cells Are Markers of Disease Activity in Multiple Sclerosis Patients
por: Dalla Libera, Dacia, et al.
Publicado: (2011)

A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia
por: Enjeti, Anoop K., et al.
Publicado: (2016)

Antidepressant activity of fingolimod in mice
por: di Nuzzo, Luigi, et al.
Publicado: (2015)

Fingolimod for Irradiation-Induced Neurodegeneration
por: Metzdorf, Judith, et al.
Publicado: (2019)

Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis
por: Racca, Vittorio, et al.
Publicado: (2019)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case report
por: Giordano, Antonino, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3grf7vg1kic3tde4beqs2715nc